Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for $620 Million in Cash and Stock
I'm PortAI, I can summarize articles.
Mirum Pharmaceuticals will acquire Bluejay Therapeutics for $620 million in cash and stock, adding brelovitug to its rare liver programs. The deal includes $250 million in cash, $370 million in stock, and potential milestone payments of $200 million. The acquisition is expected to close in Q1 2026, pending regulatory approval. Mirum plans a $200 million private placement to fund post-acquisition activities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments